Want to see GTBP full AI Analyst Report?
GTBP Stock Chart & Stats
$0.73
-$0.23(-8.01%)
At close: 4:00 PM EST
$0.73
-$0.23(-8.01%)
Day’s Range― - ―
52-Week Range$0.26 - $3.09
Previous CloseN/A
Volume15.05K
Average Volume (3M)1.63M
Market Cap
$19.96M
Enterprise Value-$4.05M
Total Cash (Recent Filing)$8.92M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Aug 12, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.46
Shares Outstanding42,312,237
10 Day Avg. Volume1,818,785
30 Day Avg. Volume1,629,462
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.75
Price to Sales (P/S)0.00
P/FCF Ratio-0.34
Enterprise Value/Market Cap-0.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.09
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageReported zero debt in 2025 and TTM materially reduces solvency and interest-rate exposure. Low leverage preserves flexibility to fund clinical programs via equity or partnerships, lowering near-term default risk and supporting multi-quarter R&D planning without debt servicing constraints.
University-sponsored GTB-5550 TrialThe University of Minnesota will sponsor the IND and early clinical trial, shifting operational and regulatory responsibilities to an academic sponsor. This partnership reduces GT Biopharma's trial execution burden, provides independent validation, and can accelerate human data generation and credibility for the platform.
Governance: Lowered QuorumReducing meeting quorum to one-third mitigates repeated adjournments and vote delays, improving corporate governance efficiency. Over time this enhances the company's ability to execute financings, approve strategic actions, and reduce solicitation costs that can otherwise impede timely corporate decisions.
Bears Say
Pre-revenue With Heavy LossesThe company remains pre-revenue with a ~-$30.9M TTM net loss, reflecting no commercial cash inflows and reliance on capital markets. Persistent operating deficits constrain self-funding, prolong dependence on external financing and raise long-term dilution and continuity risks if trials take longer than expected.
Negative Cash GenerationConsistent negative operating and free cash flow imply structural cash burn to support R&D and trials. This ongoing outflow necessitates repeat financing rounds, which can dilute equity, divert management focus to capital raises, and limit ability to sustain multi-year clinical programs without secured funding.
Equity Volatility / Funding RiskVolatile stockholders' equity (negative then modestly positive) signals prior capital strain and limited equity buffer. Such instability increases the likelihood of dilutive financings, heightens investor uncertainty, and could complicate long-term planning for costly clinical development programs.
GT Biopharma News
GTBP FAQ
What was GT Biopharma’s price range in the past 12 months?
GT Biopharma lowest stock price was $0.26 and its highest was $3.09 in the past 12 months.
What is GT Biopharma’s market cap?
GT Biopharma’s market cap is $19.96M.
When is GT Biopharma’s upcoming earnings report date?
GT Biopharma’s upcoming earnings report date is Aug 12, 2026 which is in 36 days.
How were GT Biopharma’s earnings last quarter?
GT Biopharma released its earnings results on May 18, 2026. The company reported -$0.11 earnings per share for the quarter, the consensus estimate of -$0.11 by $0.
Is GT Biopharma overvalued?
According to Wall Street analysts GT Biopharma’s price is currently Overvalued.
Does GT Biopharma pay dividends?
GT Biopharma does not currently pay dividends.
What is GT Biopharma’s EPS estimate?
GT Biopharma’s EPS estimate is -0.08.
How many shares outstanding does GT Biopharma have?
GT Biopharma has 42,312,237 shares outstanding.
What happened to GT Biopharma’s price movement after its last earnings report?
GT Biopharma reported an EPS of -$0.11 in its last earnings report, expectations of -$0.11. Following the earnings report the stock price went down -7.379%.
Which hedge fund is a major shareholder of GT Biopharma?
Currently, no hedge funds are holding shares in GTBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GT Biopharma
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced systemic mastocytosis, and other malignancies expressing CD33. The company's research also includes GTB-3650, which is in preclinical development targeting CD33 on myeloid leukemias, and GTB-5550, another preclinical asset aimed at solid tumors that are positive for B7-H3. GT Biopharma has forged key collaborations, including a co-development agreement with Altor BioScience Corporation for the clinical advancement of a 161533 TriKE fusion protein for various cancer indications. Furthermore, they maintain a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies utilizing their TriKE technology. Founded in 1965, the company previously operated as OXIS International, Inc. before rebranding to GT Biopharma, Inc. in July 2017. Its corporate operations are based in Brisbane, California.
Technical Analysis
Theriva Biologics
―
Revelation Biosciences
―
Dermata Therapeutics
―
CERo Therapeutics Holdings
―
Azitra Inc
―
Ownership Overview
2.02%
Insiders
1.13% Mutual Funds
<0.01% Other Institutional Investors
95.95% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---